
Type 1 diabetes: how interferon-α impacts human pancreatic β-cells
Decio L. Eizirik (WELBIO - ULB) and colleagues used a multi-omics approach to clarify the impact of interferon-α on human beta cells.
Decio L. Eizirik (WELBIO - ULB) and colleagues used a multi-omics approach to clarify the impact of interferon-α on human beta cells.
In a recent review paper, Decio L. Eizirik (WELBIO investigator at ULB) and colleagues discuss the mechanisms leading to pancreatic beta cell failure in diabetes.
Find on a dedicated wesite all the projects set up at ULiège and in many other organisations in the Wallonia-Brussels Federation to fight against the virus and its consequences on health, society and the economy.
L’équipe d’Abel Garcia-Pino (investigateur WELBIO – ULB) et ses collègues des universités de Hasselt et d’Umeå, percent les mystères de la régulation de la réponse stringente des bactéries par les alarmones.
Une équipe de chercheurs menée par Anna Maria Marini (WELBIO / FNRS / ULB) décrit le mécanisme moléculaire par lequel les transcepteurs Mep2 de la levure induisent la filamentation en transportant l’ammonium au travers de la membrane cellulaire.
First patients suffering from a rare disease named Glycogen Storage Disease 1B have been successfully treated with an anti-diabetes therapy. This study is led by Maria Veiga-da-Cunha (senior research associate FRS-FNRS at UCLouvain) and Emile Van Schaftingen (WELBIO investigator at UCLouvain). The results have been published in Blood. For the first time in a WELBIO project, investigators make a successful step from basic research to actual patient treatment.
Les équipes de Decio E. Eizirik et de Izortze Santin décrivent le mécanisme moléculaire par lequel un long ARN non codant spécifique régule l’inflammation des cellules beta du pancréas et contribue à la pathogenèse du diabète de type 1.